READOUT · 02 / THE PUBLISHED EVIDENCE
What the CJC-1295 studies actually measured
Dose-dependent, multi-day rises in growth hormone and IGF-1 — preserved pulsatility, a four-fold GH AUC over the unconjugated peptide, and a once-daily schedule sufficient to normalize growth in knockout mice. Each finding below is logged to its study.
What the GH and IGF-1 research shows
The CJC-1295 evidence base is biochemical and reproducible. In healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram drove mean plasma GH up 2- to 10-fold for six days or more, and IGF-1 up 1.5- to 3-fold for nine to eleven days; with repeated dosing, IGF-1 remained elevated up to 28 days, and the analog's half-life was estimated at 5.8 to 8.1 days [1]. That is the load-bearing result for the whole compound: a single dose that moves two hormones for over a week.
The preclinical work explains why the duration is so long. A screen of hGRF(1-29)-albumin bioconjugates identified CJC-1295 as the lead; in rats it produced a four-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide, remained detectable in plasma beyond 72 hours, and resisted dipeptidylpeptidase-IV in a cell-free assay [2]. The covalent albumin bond, not a slow-release formulation, is what carries the signal.
A 2009 proteomics study added a third, independent line of evidence that the axis was genuinely activated. In 11 healthy young men, CJC-1295 reproducibly shifted the serum proteome — and the immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, meaning the biochemical effect was consistent enough to track in the blood proteome and to nominate candidate biomarkers of GH/IGF-1 axis activation [5]. So three different readouts — direct GH/IGF-1 assays in humans, GH AUC in rats, and the serum proteome — converge on the same conclusion: CJC-1295 raises the GH/IGF-1 axis in a measurable, dose-dependent, sustained way.
These are the findings the CJC-1295 benefits searches are reaching for — but framed as what the GH/IGF-1 literature reports, not as outcomes promised to any person. The measurable effects in the human studies were hormonal endpoints (GH and IGF-1 concentrations), not validated clinical outcomes such as changes in body composition, strength or recovery in healthy adults; those endpoints were not the subject of the early-phase pharmacokinetic studies [1][12].
Does CJC-1295 preserve GH pulsatility?
A genuine concern with any sustained GHRH stimulus is whether it flattens the natural pulse pattern of growth hormone into a continuous plateau. CJC-1295 does not. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms per kilogram raised trough/basal GH roughly 7.5-fold and mean GH by about 46%, and IGF-1 by about 45% one week later — yet the frequency and magnitude of pulsatile GH secretion were unchanged [3]. The pituitary kept pulsing on its own schedule while the analog raised the floor it pulsed from.
That preserved pulsatility is one of the more cited properties of the molecule, because the episodic pattern of GH release is itself thought to matter for downstream signaling. The 2025 GHRH-receptor literature attributes the effect to the analog stimulating, rather than overriding, the somatotroph's endogenous secretory machinery through the Gs/cAMP/PKA/CREB cascade [13].
What the studies observed
In studies, the measurable effects of CJC-1295 were biochemical — dose-dependent, multi-day rises in GH and IGF-1 — rather than validated clinical outcomes in healthy adults. The human work was early-phase pharmacokinetics, not efficacy trials [1][3]. This describes research observations, not results a person should expect.
CJC-1295 and Ipamorelin: The Two-Receptor Rationale
The most-searched CJC-1295 pairing is with ipamorelin, and the rationale is mechanistic rather than dose-driven. GHRH analogs act on the GHRH receptor; growth-hormone-releasing peptides like ipamorelin act on a separate receptor (the ghrelin/GHS receptor). Because the two classes signal through distinct pathways, co-administration can produce supra-additive GH release — more than either alone. Ipamorelin is the selective member of its class, releasing GH with minimal effect on ACTH/cortisol or prolactin.
What is the CJC-1295 / ipamorelin combination?
A commonly discussed research pairing of a GHRH analog (CJC-1295) with a selective growth-hormone secretagogue (ipamorelin) that releases GH with minimal ACTH/cortisol or prolactin effect. The two are paired because they hit different receptors on the same secretory cell, so their GH-releasing effects can add rather than overlap.
Does the CJC-1295 + ipamorelin pairing have evidence?
GHRH and GHRP-class peptides act through distinct receptors and synergize — co-administration produces supra-additive GH release — but controlled human efficacy data specifically for the CJC-1295/ipamorelin pairing are limited. The general two-receptor synergy is well established in GH-secretagogue pharmacology; a trial validating the specific combination as administered in community settings is not [12].
CJC-1295 and ipamorelin dosing in research
Controlled human dosing for the combination is not established; forum protocols are not trial-derived. The research rationale for pairing is two-receptor synergy (a GHRH analog plus a selective GHRP), not a validated dose. No human dosing for the pairing is recommended here. For the doses that do appear in controlled CJC-1295 studies, see doses used in research.
What the broader and recent literature adds
Beyond the core pharmacokinetic papers, CJC-1295 shows up across structural, analytical and review literature. A 2009 proteomics study in 11 healthy young men found that CJC-1295 reproducibly shifted the serum proteome — decreasing apolipoprotein A1 and a transthyretin isoform, increasing a C-terminal albumin fragment and immunoglobulin species — with the immunoglobulin/albumin-fragment signal correlating linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [5]. In an anti-doping context, high-resolution LC-MS/MS definitively identified CJC-1295 as the active ingredient in an unknown "GHRH" preparation seized from the black market [6].
The GHRH-knockout mouse work anchors the in-vivo case. Two micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length in GHRH-knockout mice and raised pituitary GH mRNA, while dosing every 48 to 72 hours was progressively less effective — direct evidence that the long-acting analog's once-daily schedule is sufficient to restore GH-axis-dependent growth [4]. Recent reviews place all of this in context: the 2025 Nature Reviews Endocrinology synthesis of GHRH analogs [12], a 2025 review of GHRH-receptor signaling [13], and a 2026 review assessing the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions, which directly addresses the evidence gap for unapproved GH-axis peptides [14].